LPWM
ABUS icon

Lake Point Wealth Management’s Arbutus Biopharma ABUS Stock Holding History

Lake Point Wealth Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$0 Hold
100
– – ﹤0.01% 436
2022
Q1 		$0 Hold
100
– – ﹤0.01% 417
2021
Q4 		$0 Buy
+100
New +$388 ﹤0.01% 433

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lake Point Wealth Management's ABUS Position: Q2 2022 in Review

Lake Point Wealth Management held its Arbutus Biopharma (ABUS) position steady in Q2 2022 at 100 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #436.

Lake Point Wealth Management first reported a position in ABUS in Q4 2021 and has held it in 3 quarters since. 113 funds tracked by Wall St. Rank hold ABUS as of Q2 2022.

  • Lake Point Wealth Management held 100 shares of Arbutus Biopharma worth $0 as of Q2 2022.
  • Lake Point Wealth Management left its Arbutus Biopharma share count unchanged in Q2 2022.
  • Arbutus Biopharma made up ﹤0.01% of Lake Point Wealth Management's portfolio in Q2 2022, its #436 holding.
  • Lake Point Wealth Management first reported a position in Arbutus Biopharma in Q4 2021 and has held it in 3 quarters since.
  • 113 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2022.

Based on Lake Point Wealth Management's 13F filing for Q2 2022, filed 19 Jul 2022.